{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:31:54Z","timestamp":1740148314989,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The intense competition for resources to combat COVID-19 has greatly reduced access to health care for patients with other diseases. After the disastrous overrun of hospitals through COVID-19 patients in some jurisdictions, availability of resources for \u2018elective\u2019 medical procedures, including care for the chronically ill, has been greatly reduced in many places as a pre-emptive measure before or during the blooming of infection clusters. Pharmaceutical companies have either stopped recruitment or even cancelled ongoing clinical trials in chronic diseases. Pre-emptive triage and its impact on medical ethics is discussed in the framework of care for inflammatory bowel disease.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaa127","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T19:13:29Z","timestamp":1591989209000},"page":"1765-1768","source":"Crossref","is-referenced-by-count":0,"title":["Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act"],"prefix":"10.1093","volume":"14","author":[{"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany"},{"name":"Excellence Cluster Precision Medicine in Inflammation, Christian-Albrechts-University, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Hospital, Frankfurt\/Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Rogge","sequence":"additional","affiliation":[{"name":"Institute of Experimental Medicine, Medical Ethics. University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL, USA"},{"name":"MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"2020120619120754900_CIT0001","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/gut.39.5.690","article-title":"Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease [EC-IBD]","volume":"39","author":"Shivananda","year":"1996","journal-title":"Gut"},{"key":"2020120619120754900_CIT0002","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(20)30076-5","article-title":"Implications of COVID-19 for patients with pre-existing digestive diseases","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020120619120754900_CIT0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2020120619120754900_CIT0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2020120619120754900_CIT0005","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2020120619120754900_CIT0006","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/j.gastro.2019.08.020","article-title":"Competition for clinical trials in inflammatory bowel diseases","volume":"157","author":"Harris","year":"2019","journal-title":"Gastroenterology"},{"key":"2020120619120754900_CIT0007","article-title":"How deadly is COVID-19? A rigorous analysis of excess mortality and age-dependent fatality rates in Italy","author":"Modi","year":"2020","journal-title":"medRxiv preprint"},{"author":"Federal Statistical Office of Germany","key":"2020120619120754900_CIT0008"},{"key":"2020120619120754900_CIT0009"},{"key":"2020120619120754900_CIT0010"},{"volume-title":"Ethical Framework","year":"2020","author":"Berlinger","key":"2020120619120754900_CIT0011"},{"volume-title":"Legal and Ethical Issues in Healthcare Policy","year":"2009","author":"The elderly","key":"2020120619120754900_CIT0012"},{"key":"2020120619120754900_CIT0013"},{"key":"2020120619120754900_CIT0014"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa127\/33643561\/jjaa127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/12\/1765\/34665125\/jjaa127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/12\/1765\/34665125\/jjaa127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T01:38:32Z","timestamp":1607305112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/12\/1765\/5862397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa127","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"type":"print","value":"1873-9946"},{"type":"electronic","value":"1876-4479"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,6,25]]}}}